CompletedNCT01389206
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actelion
- Principal Investigator
- Vallerie McLaughlin, MDUniversity of Michigan
- Intervention
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi(drug)
- Enrollment
- 797 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2018
Study locations (30)
- Cardiovascular Associates, PC, Birmingham, Alabama, United States
- University of South Alabama Medical Center, Mobile, Alabama, United States
- Pulmonary Associates, Phoenix, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Alliance Medical and Research Center, Fountain Valley, California, United States
- Scripps Clinic, Scripps Green Hospital, La Jolla, California, United States
- University of Southern California, Los Angeles, California, United States
- Paloma Medical Group, San Juan Capistrano, California, United States
- Harbor-UCLA Medical Center, Torrance, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- South Denver Cardiology Associates PC, Littleton, Colorado, United States
- Robert E. Benkert, M.D.P.C., Wheat Ridge, Colorado, United States
- Lung Health & Sleep Enhancement Center, LLC, Newark, Delaware, United States
- Bay Area Cardiology Research, P.A., Brandon, Florida, United States
- Bay Area Chest Physicians, Clearwater, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Canadian Heart Research Centre
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01389206 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGNANCT07366879Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial HypertensionGolden Jubilee National Hospital
- RECRUITINGPHASE3NCT07245680COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →